AU2015350559C1 - Methods of modulating drug plasma levels using erythrohydroxybupropion - Google Patents
Methods of modulating drug plasma levels using erythrohydroxybupropion Download PDFInfo
- Publication number
- AU2015350559C1 AU2015350559C1 AU2015350559A AU2015350559A AU2015350559C1 AU 2015350559 C1 AU2015350559 C1 AU 2015350559C1 AU 2015350559 A AU2015350559 A AU 2015350559A AU 2015350559 A AU2015350559 A AU 2015350559A AU 2015350559 C1 AU2015350559 C1 AU 2015350559C1
- Authority
- AU
- Australia
- Prior art keywords
- dextromethorphan
- bupropion
- day
- administered
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Addiction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201548A AU2019201548C1 (en) | 2014-11-21 | 2019-03-06 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2021200981A AU2021200981B2 (en) | 2014-11-21 | 2021-02-15 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2024219871A AU2024219871A1 (en) | 2014-11-21 | 2024-09-19 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 | 2014-11-21 | ||
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/555,085 | 2014-11-26 | ||
| US14/554,947 | 2014-11-26 | ||
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,988 | 2014-11-26 | ||
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/602,177 | 2015-01-21 | ||
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/604,397 | 2015-01-23 | ||
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/617,624 | 2015-02-09 | ||
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| US14/628,062 | 2015-02-20 | ||
| PCT/US2015/028901 WO2016081027A1 (en) | 2014-11-21 | 2015-05-01 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201548A Division AU2019201548C1 (en) | 2014-11-21 | 2019-03-06 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2015350559A1 AU2015350559A1 (en) | 2017-06-08 |
| AU2015350559B2 AU2015350559B2 (en) | 2018-12-06 |
| AU2015350559C1 true AU2015350559C1 (en) | 2019-07-11 |
Family
ID=56014366
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015350559A Active AU2015350559C1 (en) | 2014-11-21 | 2015-05-01 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2019201548A Active AU2019201548C1 (en) | 2014-11-21 | 2019-03-06 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2021200981A Active AU2021200981B2 (en) | 2014-11-21 | 2021-02-15 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2024219871A Pending AU2024219871A1 (en) | 2014-11-21 | 2024-09-19 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201548A Active AU2019201548C1 (en) | 2014-11-21 | 2019-03-06 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2021200981A Active AU2021200981B2 (en) | 2014-11-21 | 2021-02-15 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| AU2024219871A Pending AU2024219871A1 (en) | 2014-11-21 | 2024-09-19 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP3220909B1 (enExample) |
| JP (5) | JP6602863B2 (enExample) |
| KR (7) | KR102376868B1 (enExample) |
| CN (2) | CN107205998A (enExample) |
| AU (4) | AU2015350559C1 (enExample) |
| CA (3) | CA2968371C (enExample) |
| CY (1) | CY1123571T1 (enExample) |
| DK (1) | DK3220909T3 (enExample) |
| ES (1) | ES2835304T3 (enExample) |
| HR (1) | HRP20201855T1 (enExample) |
| HU (1) | HUE052609T2 (enExample) |
| IL (4) | IL297349B2 (enExample) |
| LT (1) | LT3220909T (enExample) |
| MX (3) | MX2017006653A (enExample) |
| MY (1) | MY189466A (enExample) |
| PL (1) | PL3220909T3 (enExample) |
| PT (1) | PT3220909T (enExample) |
| RS (1) | RS61113B1 (enExample) |
| SG (2) | SG11201704066VA (enExample) |
| SI (1) | SI3220909T1 (enExample) |
| SM (1) | SMT202000639T1 (enExample) |
| WO (1) | WO2016081027A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| CA2968371C (en) * | 2014-11-21 | 2020-08-18 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| CR20210368A (es) * | 2019-01-07 | 2021-12-10 | Antecip Bioventures Ii Llc | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2015069809A1 (en) * | 2013-11-05 | 2015-05-14 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| MX2008009947A (es) * | 2006-02-03 | 2008-10-20 | Avanir Pharmaceuticals | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) * | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| CA2968371C (en) | 2014-11-21 | 2020-08-18 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
-
2015
- 2015-05-01 CA CA2968371A patent/CA2968371C/en active Active
- 2015-05-01 AU AU2015350559A patent/AU2015350559C1/en active Active
- 2015-05-01 MY MYPI2017701828A patent/MY189466A/en unknown
- 2015-05-01 KR KR1020217014289A patent/KR102376868B1/ko active Active
- 2015-05-01 EP EP15861189.7A patent/EP3220909B1/en active Active
- 2015-05-01 RS RS20201405A patent/RS61113B1/sr unknown
- 2015-05-01 PL PL15861189T patent/PL3220909T3/pl unknown
- 2015-05-01 MX MX2017006653A patent/MX2017006653A/es unknown
- 2015-05-01 PT PT158611897T patent/PT3220909T/pt unknown
- 2015-05-01 IL IL297349A patent/IL297349B2/en unknown
- 2015-05-01 CA CA3082645A patent/CA3082645C/en active Active
- 2015-05-01 KR KR1020187036244A patent/KR102253986B1/ko active Active
- 2015-05-01 KR KR1020177017050A patent/KR101931896B1/ko active Active
- 2015-05-01 CA CA3232022A patent/CA3232022A1/en active Pending
- 2015-05-01 MX MX2021001442A patent/MX2021001442A/es unknown
- 2015-05-01 CN CN201580074124.7A patent/CN107205998A/zh active Pending
- 2015-05-01 KR KR1020227008513A patent/KR102524253B1/ko active Active
- 2015-05-01 HR HRP20201855TT patent/HRP20201855T1/hr unknown
- 2015-05-01 HU HUE15861189A patent/HUE052609T2/hu unknown
- 2015-05-01 IL IL314982A patent/IL314982A/en unknown
- 2015-05-01 JP JP2017527254A patent/JP6602863B2/ja active Active
- 2015-05-01 LT LTEP15861189.7T patent/LT3220909T/lt unknown
- 2015-05-01 SG SG11201704066VA patent/SG11201704066VA/en unknown
- 2015-05-01 KR KR1020247005737A patent/KR102822654B1/ko active Active
- 2015-05-01 KR KR1020257019724A patent/KR20250092295A/ko active Pending
- 2015-05-01 EP EP20193845.3A patent/EP3763372A1/en active Pending
- 2015-05-01 DK DK15861189.7T patent/DK3220909T3/da active
- 2015-05-01 IL IL280905A patent/IL280905B2/en unknown
- 2015-05-01 ES ES15861189T patent/ES2835304T3/es active Active
- 2015-05-01 SM SM20200639T patent/SMT202000639T1/it unknown
- 2015-05-01 KR KR1020237012943A patent/KR102640586B1/ko active Active
- 2015-05-01 WO PCT/US2015/028901 patent/WO2016081027A1/en not_active Ceased
- 2015-05-01 CN CN202010202397.8A patent/CN111297860A/zh active Pending
- 2015-05-01 SI SI201531421T patent/SI3220909T1/sl unknown
- 2015-05-02 SG SG10201911873XA patent/SG10201911873XA/en unknown
-
2017
- 2017-05-19 MX MX2023000320A patent/MX2023000320A/es unknown
- 2017-05-21 IL IL252417A patent/IL252417B/en active IP Right Grant
-
2019
- 2019-03-06 AU AU2019201548A patent/AU2019201548C1/en active Active
- 2019-10-09 JP JP2019185676A patent/JP6842129B2/ja active Active
-
2020
- 2020-11-24 CY CY20201101110T patent/CY1123571T1/el unknown
-
2021
- 2021-02-04 JP JP2021016211A patent/JP7226839B2/ja active Active
- 2021-02-15 AU AU2021200981A patent/AU2021200981B2/en active Active
-
2023
- 2023-02-02 JP JP2023014583A patent/JP2023041862A/ja active Pending
-
2024
- 2024-09-19 AU AU2024219871A patent/AU2024219871A1/en active Pending
-
2025
- 2025-05-07 JP JP2025077089A patent/JP2025105965A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2015069809A1 (en) * | 2013-11-05 | 2015-05-14 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Non-Patent Citations (1)
| Title |
|---|
| KOTLYAR M. et al., "Inhibition of CYP2D6 activity by bupropion", Journal of Clinical Psychopharmacology, June 2005, Vol. 25, No. 3, pages 226-229 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200981B2 (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| US9408815B2 (en) | Bupropion as a modulator of drug activity | |
| US9278095B2 (en) | Bupropion as a modulator of drug activity | |
| US9421176B1 (en) | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects | |
| AU2018203638B2 (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| US9457025B2 (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan | |
| HK40035510A (en) | Treatments comprising a combination of dextromethorphan and bupropion | |
| HK1243323B (en) | Bupropion for modulating drug plasma levels of dextrometorphan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 APR 2019 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 APR 2019 |